

	Median TTP (95% CI)	P value (vs. Cohort B)
All patients	Not reached	–
Cohort A	Not reached	–
Cohort B	15.7 (9.3–15.7)	–
Cohort C	Not reached	0.03

	Median TTP (95% CI)	P value (vs. Cohort B)
All patients	19.4 (15.2–20.9)	–
Cohort A	Not reached	–
Cohort B	9.3 (4.6–9.3)	–
Cohort C	20.9 (15.4–20.9)	0.04

Figure S1 TTP of target tumor(s) (A) and those of hepatic tumors (B). Cohort A, patients with incomplete lipiodol uptake on non-enhanced CT immediately after transarterial chemoembolization who underwent additional treatment before the follow-up; Cohort B, patients with incomplete lipiodol uptake on non-enhanced CT immediately after transarterial chemoembolization without additional treatment before follow-up; Cohort C, patients with complete lipiodol uptake on non-enhanced CT immediately after transarterial chemoembolization. Similar to the overall TTP, the target TTP and hepatic TTP both showed significant differences between Cohort B and Cohort C. TTP, time to progression; CI, confidence interval; CT, computed tomography.

https://dx.doi.org/10.21037/jgo-24-134